---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-031671"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2026-08-06T20:06:10+00:00"
generated_at: "2026-08-06T20:08:43.367653+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics raises $10M in private placement; extends cash runway to end of 2028

## Summary
- Issued 4,761,904 shares at $2.10/share for gross proceeds of $10M; closed August 6, 2026.
- Net proceeds plus existing cash expected to extend cash runway to end of calendar 2028.
- Dual-source manufacturing strategy for GTx-104 initiated; NDA resubmission timing depends on manufacturing readiness.
- Technology transfer to a U.S.-based contract manufacturer is underway.
- Craig-Hallum acted as sole placement agent for the private placement.

## SEC filing metadata
- accession: 0001140361-26-031671
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2026-08-06T20:06:10+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036126031671/0001140361-26-031671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036126031671/ef20079559_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-031671
- JSON: https://secwatch.observer/filing/0001140361-26-031671.json
- Plain text: https://secwatch.observer/filing/0001140361-26-031671.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.